2022
Ramatroban for chemoprophylaxis and treatment of COVID-19: David takes on Goliath
Chiang K, Rizk J, Nelson D, Krishnamurti L, Subbian S, Imig J, Khan I, Reddy S, Gupta A. Ramatroban for chemoprophylaxis and treatment of COVID-19: David takes on Goliath. Expert Opinion On Therapeutic Targets 2022, 26: 13-28. PMID: 35068281, PMCID: PMC10119876, DOI: 10.1080/14728222.2022.2031975.Peer-Reviewed Original ResearchConceptsCOVID-19 pneumoniaDP2 receptorLong-haul COVID-19COVID-19Dual receptor antagonistProgressive lung injuryRapid symptomatic reliefRole of TXAAcute respiratory distressMaladaptive immune responsesThromboxane prostanoid (TP) receptorFatty acid levelsLung injuryRespiratory distressSymptomatic reliefDual antagonismRespiratory dysfunctionImmunomodulatory agentsRapid reliefReceptor antagonistAntifibrotic agentsCyclooxygenase metabolitesImmune responseProstanoid receptorsSystemic circulation
2015
Platelet transfusions in platelet consumptive disorders are associated with arterial thrombosis and in-hospital mortality
Goel R, Ness P, Takemoto C, Krishnamurti L, King K, Tobian A. Platelet transfusions in platelet consumptive disorders are associated with arterial thrombosis and in-hospital mortality. Blood 2015, 125: 1470-1476. PMID: 25588677, PMCID: PMC4342358, DOI: 10.1182/blood-2014-10-605493.Peer-Reviewed Original ResearchConceptsImmune thrombocytopenic purpuraThrombotic thrombocytopenic purpuraAcute myocardial infarctionPlatelet transfusionsArterial thrombosisVenous thrombosisHigher oddsHospital mortalityThrombocytopenic purpuraGender-adjusted odds ratioPlatelet transfusion practicesNationwide Inpatient SampleConsumptive disordersHIT patientsTransfusion practiceInpatient SampleMyocardial infarctionClinical severityOdds ratioTransfusionThrombosisPrimary mediatorMortalityLittle dataPurpura